Is CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) suited for growth investing?

In this article we will dive into CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) as a possible candidate for growth investing. Investors should always do their own research, but we noticed CATALYST PHARMACEUTICALS INC showing up in our Louis Navellier growth screen, which makes it worth to investigate a bit more.

Key Considerations for Growth Investors.

• With a favorable Return on Equity (ROE) of 22.52%, CATALYST PHARMACEUTICALS INC demonstrates its ability to deliver attractive returns for shareholders. This metric highlights the company's effective management of assets and its profitability.
• CATALYST PHARMACEUTICALS INC has a strong history of beating EPS estimates in the last 4 quarters, signaling its ability to consistently exceed market expectations. This indicates the company's strong financial performance and its potential for creating shareholder value.
• With notable 1-year revenue growth of 23.47%, CATALYST PHARMACEUTICALS INC exemplifies its ability to generate increased sales and revenue streams. This growth signifies the company's strong business performance and its potential for future growth.
• CATALYST PHARMACEUTICALS INC has demonstrated strong quarter-to-quarter (Q2Q) revenue growth of 28.26%, reflecting its ability to generate consistent increases in sales. This growth highlights the company's effective market positioning and its potential for continued success.
• The operating margin of CATALYST PHARMACEUTICALS INC has seen steady growth over the past year, signaling improved profitability. This trend indicates the company's effective cost management and its ability to generate higher returns.
• With positive growth in its free cash flow (FCF) over the past year, CATALYST PHARMACEUTICALS INC showcases its ability to generate strong cash flows and maintain a solid financial position. This growth reflects the company's efficient utilization of capital and its commitment to long-term value creation.
• The earnings per share (EPS) of CATALYST PHARMACEUTICALS INC have shown positive growth on a quarter-to-quarter (Q2Q) basis, with a 41.94% increase. This reflects the company's ability to improve its profitability over time.
• CATALYST PHARMACEUTICALS INC has seen a 4.55% change in the average next Quarter EPS Estimate by analysts over the last 3 months, signaling the shifting perception of the company's EPS outlook.
• The quarterly earnings of CATALYST PHARMACEUTICALS INC have shown a 41.94% increase compared to the previous quarter, as revealed in the recent financial report. This growth signifies positive momentum in the company's financials, pointing towards a promising upward trend
• accelerating EPS growth for CATALYST PHARMACEUTICALS INC: the current Q2Q growth of 41.94% exceeds the previous year Q2Q growth of 40.91%.

How does the complete fundamental picture look for NASDAQ:CPRX?

Every day, ChartMill assigns a Fundamental Rating to each stock, providing a score ranging from 0 to 10. This rating is determined by evaluating various fundamental indicators and properties.

We assign a fundamental rating of 8 out of 10 to CPRX. CPRX was compared to 571 industry peers in the Biotechnology industry. Both the health and profitability get an excellent rating, making CPRX a very profitable company, without any liquidiy or solvency issues. CPRX has both an excellent growth and valuation score. This means it is growing and it is still cheap. This is a rare combination! This makes CPRX very considerable for value and growth and quality investing!

Check the latest full fundamental report of CPRX for a complete fundamental analysis.

More growth stocks can be found in our Lois Navellier screen.

Keep in mind

This article should in no way be interpreted as advice. The article is based on the observed metrics at the time of writing, but you should always make your own analysis and trade or invest at your own responsibility.